Prothena Corporation plc Q4 FY2024 earnings call

• Prothena's mission is to create transformational therapies for protein dysregulation diseases.
• The company has a robust portfolio of wholly-owned and partnered therapeutic candidates targeting neurodegenerative and rare peripheral amyloid diseases.
• Wholly-owned clinical programs are nearing inflection points in 2025: Birtamimab's Phase 3 AFFIRM-AL trial expects top-line results in Q2 2025, PRX012's Phase 1 ASCENT trials have mid-year data expected, and PRX123 continues in development.
• Partnerships with Roche, Novo Nordisk, Bristol Myers Squibb: Updates on prasinezumab, coramitug, BMS-986446, and PRX019.
• 2024 financial results were in-line with guidance, with $472.2 million in cash as of Dec 31, 2024.

No detailed breakdown of financial performance by product segments with absolute terms and revenue contribution % provided in the transcript.

• 2025 net cash used in operating and investing activities expected to be between $168 million and $175 million.
• Expected cash position at year-end 2025 is approximately $301 million.
• Estimated 2025 net loss is $197 million to $205 million, including $41 million in non-cash share-based compensation expense.

Forward-looking statements are subject to risks, uncertainties, and factors that could cause actual results to differ, but no specific risks are detailed in the provided transcript.

Q: About birtamimab's Phase 3 AFFIRM-AL trial and market opportunity A: Gene and Brandon discussed the unmet need, SPA agreement with FDA, and market potential Q: Baseline characteristics of AFFIRM-AL patients and clinically meaningful OS benefit A: Chad discussed baseline similarity to VITAL and p-value expectation Q: Long-term mortality trends, TEAE deaths, and dFLC A: Gene and Chad addressed mortality trends and TEAE details Q: Statistical significance vs clinical meaningfulness for PRX012 A: Brandon and Gene talked about market research and KOL interest Q: PRX012 data and late-stage development A: Mark discussed mid-year data from ASCENT trials Q: Phase 3 AL amyloidosis study and PRX012 expansion cohort A: Brandon and Chad discussed control arm expectations and expansion cohort rationale Q: Commercial uptake and label expansion for birtamimab A: Gene and Brandon talked about patient identification and label potential Q: Commercial infrastructure and European path A: Gene and Brandon discussed commercial build-out and European regulatory alignment